New Drug Reviews

Crisaborole (Eucrisa) for Mild to Moderate Atopic Dermatitis


Am Fam Physician. 2018 Sep 15;98(6):379-380.

Crisaborole (Eucrisa) is a topical nonsteroid treatment for mild to moderate atopic dermatitis in children two years and older.1 It is a phosphodiesterase-4 inhibitor, although its mechanism of action for atopic dermatitis is unknown.

 Enlarge     Print

DrugDosageDose formCost*

Crisaborole (Eucrisa)

Apply ointment in thin layer twice daily to affected areas

2% crisaborole ointment

$637 for a 60-g tube

*—Estimated retail price of one month's treatment based on information obtained at (accessed February 23, 2018).

DrugDosageDose formCost*

Crisaborole (Eucrisa)

Apply ointment in thin layer twice daily to affected areas

2% crisaborole ointment

$637 for a 60-g tube

*—Estimated retail price of one month's treatment based on information obtained at (accessed February 23, 2018).


Studies have shown crisaborole to be safe with few adverse effects. The three most common adverse effects are application site infection (1.2%), burning or stinging with application (2.3%), and worsening dermatitis (3.1%).2 A year-long study of 517 children and adults did not report adverse effects commonly associated with topical corticosteroid treatment, such as skin thinning, striae, or adrenal axis suppression.3 Hypersensitivity reactions, such as contact urticaria, rarely occur.1 There are no available data on the safety of crisaborole in women who are pregnant or breastfeeding, children younger than two years, or adults 65 years and older.


Crisaborole is well tolerated by most patients. Only 1.7% of patients will discontinue treatment because of adverse effects.3


Crisaborole improves lesion clearing and pruritus in patients with atopic dermatitis to a greater extent than emollient treatment alone.2 In two studies with a total of 1,522 patients who had mild to moderate atopic dermatitis, significantly more patients treated with crisaborole achieved results of “clear” or “almost clear” as evaluated by investigators, compared with treatment using only emollient ointment (32.8% vs. 25.4% in study 1, and 31.4% vs. 18% in study 2).2 These results reflect at least a two-point improvement in lesion clearing on a five-point assessment, which is clinically meaningful. One additional patient will respond for every eight to 14 patients treated with crisaborole compared with emollient ointment alone. Pruritus responds in a few days to use of crisaborole or emollient ointment, but more patients will experience further clearing with crisaborole after about one week of treatment. There are no data on long-term effectiveness because studies have lasted for only 28 days. Crisaborole has not been compared directly with topical corticosteroids or other treatments for atopic dermatitis.


A one-month supply of crisaborole (one 60-g tube) is approximately $637. This is substantially more expensive than generic topical corticosteroids such as triamcinolone, which costs about $6 for a 30-day supply (one 15-g tube). Crisaborole may require prior authorization for insurance coverage, including documented treatment failure with other medications.


Patients should apply a thin layer of crisaborole to the affected area twice daily. The dosing and patient directions are similar to those of already available products, although some topical corticosteroids can be used once daily.

Bottom Line

Crisaborole has been shown to be effective in about one-third of patients who use it, but it is much more expensive than other available products. Although crisaborole is a safe option for patients in whom topical corticosteroids are considered risky (e.g., children at least two years of age), it should not be routinely considered until long-term effectiveness and safety data become available.

Author disclosure: No relevant financial affiliations.

Address correspondence to Gregory Castelli, PharmD, BCPS, BC-ADM, at Reprints are not available from the authors.


1. Daily Med. Drug label information. Eucrisa—crisaborole ointment. Accessed November 12, 2017.

2. Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults [published correction appears in J Am Acad Dermatol. 2017;76(4):777]. J Am Acad Dermatol. 2016;75(3):494–503.e6.

3. Eichenfield LF, Call RS, Forsha DW, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77(4):641–649.e5.

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, MMedEd, Assistant Medical Editor.

A collection of STEPS published in AFP is available at



Copyright © 2018 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

More in AFP

Editor's Collections

Related Content

More in Pubmed


Sep 2021

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article